Map of Mifepristone Approvals

Gynuity Health Projects monitors the approval status of mifepristone across the globe. The map provided reflects our most recent information about where the medication is available. If you notice any inaccuracies or learn of new approvals, you are encouraged to contact us at pubinfo@gynuity.org.

Mifepristone was first approved by France and China in 1988. To our knowledge, Japan and Tanzania are the latest countries to authorize its use in 2023 and 2024, respectively.

Mifepristone is most commonly known for its use to terminate a pregnancy. It functions by reducing the biological availability of progesterone, a hormone essential for maintaining pregnancy. For effective results, it is used in combination with misoprostol, which induces uterine contractions to facilitate emptying of the uterus.

Mifepristone is used for alternative indications, including the treatment of early pregnancy loss and intrauterine fetal demise.